Alliance for Less-Invasive Heart Valve Replacement

An agreement to support the development of new products for less-invasive heart valve replacement surgeries has been announced by 3F Therapeutics, Inc. (Lake, Forest, CA, USA) and Percutaneous Valve Technologies, Inc. (PTV, Fort Lee, NJ, USA).

PTV is giving 3F an exclusive license and components of its valve technology for cardiac surgery market applications, aimed at the development, qualification, and eventual marketing of new minimally invasive products. PTV's less-invasive technology blends proprietary balloon-expandable stent technology with a bioprosthetic valve made from biologic tissue. The procedure deploys the stent across the old valve, holding it permanently open and allowing for replacement of the old stenotic valve with a new one, obviating the need for removing the failing valve. The new valve is designed to be delivered in a cardiac catheterization laboratory under local anesthesia, using fluoroscopic guidance.

"3F has confirmed the market opportunity for PVT's unique technology in the surgical suite, expanding it beyond the patients who will be treated by the cardiologist,” said Stanton Rowe, president and CEO of PVT. "With the 3F agreement, PVT will continue its focus on cardiology applications, while 3F will develop surgical applications, as these are the respective areas of our companies' expertise.”




Related Links:
3F Therapeutics, Inc
Valve Technologies, Inc.